NCT04366323View on ClinicalTrials.gov

Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

Sars-CoV2

Interventions

DRUG

ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

Two doses of 80 million adipose-tissue derived mesenchymal stem cells

Trial Locations (6)

11407

Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera

14004

Hospital Reina Sofía, Córdoba

18014

Hospital Universitario Virgen de las Nieves, Granada

41009

Hospital Universitario Virgen Macarena, Seville

41013

Hospital Unversitario Virgen del Rocío, Seville

41014

Hospital Nuestra Señora de Valme, Seville

All Listed Sponsors

lead

Andalusian Network for Design and Translation of Advanced Therapies

OTHER

NCT04366323 - Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 | Biotech Hunter | Biotech Hunter